<div id="readability-page-1"><div><div>                                                                                                                                                <p>The oil crisis amid the Iran conflict is occupying investor attention. But stock markets need to turn their attention back to tariffs.</p><p>On April 2, Bloomberg reported that the Trump administration planned to hit the pharmaceutical sector with tariffs. Firms that did not agree to lower U.S. drug prices are subject to tariffs. Trump last threatened tariffs of 100% to 200%.</p><p>Drug companies that agreed to a pricing deal included Pfizer (PFE), Sanofi (SNY), Novartis (NVS), Bristol-Myers Squibb (BMY), Eli Lilly (LLY), and Novo Nordisk (NVO).</p><p>Investors might need to wait for the mid-term elections. The GOP might lose votes. If that happens, drug companies may set drug prices that align with their research and marketing costs.</p><p>Watch out for the steel and aluminum sectors. The Trump administration might impose 25% tariffs on finished products made with those imported metals. Commodity-grade steel and aluminum products face 50% tariffs. The stocks that might face selling pressure include Nucor (NUE), Steel Dynamics (STLD), ArcelorMittal (MT), and Cleveland-Cliffs (CLF).</p><p>Tariffs on those two metals will hurt small businesses the most. Firms of that size need to keep adjusting their operating model whenever tariff rates change frequently.</p><p>Your Takeaway</p><p>Tariffs will add to inflation. With oil prices going up, the two headwinds ahead will hurt consumers.<br/></p></div></div></div>

ARKG

<p>The Trump administration is considering imposing tariffs on the pharmaceutical sector, targeting companies that do not agree to lower drug prices, with potential rates of 100% to 200%. Companies like Pfizer and Novartis have agreed to pricing deals. Additionally, 25% tariffs may be applied to finished products made from imported steel and aluminum, with commodity-grade products facing 50% tariffs. This could negatively impact small businesses and contribute to inflation, especially with rising oil prices.</p>

- The oil crisis related to the Iran conflict is currently drawing investor focus, but attention is shifting back to impending tariffs on the pharmaceutical sector.  
- The Trump administration is preparing to impose tariffs between 100% and 200% on drug companies failing to reduce U.S. drug prices, while also considering 25% tariffs on finished steel and aluminum products.  
- These tariffs are expected to contribute to inflation and create challenges for consumers and small businesses facing fluctuating costs.

Baystreet

Ark Genomic Revolution ETF

iShares Biotechnology ETF

iShares Global Healthcare

Health Care Select Sector SPDR

Pfizer

iShares US Pharma

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

Hwabao WP CSI Pharmaceuticals ETF

E Fund CSI Biotechnology Theme ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Minsheng Royal CSI Biotechnology Theme ETF

Direxion Daily Biotech Top 5 Bull 2X ETF

NOVARTIS AG

Invesco Nasdaq Biotechnology ETF

E Fund CSI 300 Health Care ETF

Proshares Ultra Nasdaq Biotech

ChinaAMC SSE STAR Biology and Medicine ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

VG Health

Invesco Biotechnology & Genome ETF

China Merchants CSI Biotechnology Theme ETF

Menovo

ALPS Medical Breakthrough

Tianhong CNI BIOMEDICINE ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Tariff Watch Warning on These Two Sectors